LeMaitre Vascular, Inc. (NASDAQ:LMAT – Get Free Report) declared a quarterly dividend on Tuesday, October 27th. Stockholders of record on Thursday, November 19th will be paid a dividend of $0.25 per share by the medical instruments supplier on Thursday, December 3rd. This represents a $1.00 dividend on an annualized basis and a dividend yield of 1.3%. The ex-dividend date is Thursday, November 19th.
LeMaitre Vascular has increased its dividend payment by an average of 0.2% annually over the last three years and has increased its dividend annually for the last 14 consecutive years. LeMaitre Vascular has a payout ratio of 42.0% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect LeMaitre Vascular to earn $3.15 per share next year, which means the company should continue to be able to cover its $1.00 annual dividend with an expected future payout ratio of 31.7%.
LeMaitre Vascular Price Performance
Shares of NASDAQ LMAT opened at $77.01 on Tuesday. LeMaitre Vascular has a twelve month low of $76.60 and a twelve month high of $118.01. The business’s 50 day moving average price is $81.24 and its two-hundred day moving average price is $93.91. The company has a quick ratio of 12.54, a current ratio of 14.60 and a debt-to-equity ratio of 0.39. The company has a market cap of $1.76 billion, a PE ratio of 28.24, a price-to-earnings-growth ratio of 2.29 and a beta of 0.51.
LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The medical instruments supplier reported $0.65 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.69 by ($0.04). LeMaitre Vascular had a return on equity of 15.33% and a net margin of 23.51%. The company had revenue of $67.97 million for the quarter, compared to analyst estimates of $67.39 million. During the same quarter last year, the business earned $0.75 earnings per share. The company’s revenue was up 11.3% on a year-over-year basis. On average, analysts predict that LeMaitre Vascular will post 2.83 EPS for the current year.
Wall Street Analyst Weigh In
LMAT has been the topic of several recent analyst reports. Barrington Research lowered shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 5th. Weiss Ratings downgraded shares of LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday, October 23rd. Wall Street Zen downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Citizens Jmp initiated coverage on LeMaitre Vascular in a research note on Thursday, November 5th. They set a “market outperform” rating and a $110.00 target price for the company. Finally, Seaport Research Partners set a $110.00 price target on LeMaitre Vascular in a report on Thursday, November 5th. Three investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $108.25.
Check Out Our Latest Report on LeMaitre Vascular
LeMaitre Vascular Company Profile
LeMaitre Vascular develops, manufactures and markets medical devices used primarily in the treatment of vascular disease. Its products support procedures performed by vascular surgeons and include vascular grafts, embolectomy catheters, carotid shunts, valvulotomes and other instruments used in vascular surgery. Founded in 1983 by vascular surgeon George LeMaitre, the company is headquartered in Burlington, Massachusetts. Its products are sold to hospitals and medical professionals around the world through a combination of direct sales and distributors.
Further Reading
- Five stocks we like better than LeMaitre Vascular
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.
